625 related articles for article (PubMed ID: 25383523)
41. Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3.
Wang YD; Chen WD; Li C; Guo C; Li Y; Qi H; Shen H; Kong J; Long X; Yuan F; Wang X; Huang W
Mol Endocrinol; 2015 Feb; 29(2):322-31. PubMed ID: 25496033
[TBL] [Abstract][Full Text] [Related]
42. Antiatherosclerotic effect of farnesoid X receptor.
Mencarelli A; Renga B; Distrutti E; Fiorucci S
Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H272-81. PubMed ID: 19028791
[TBL] [Abstract][Full Text] [Related]
43. Phosphorylation of hepatic farnesoid X receptor by FGF19 signaling-activated Src maintains cholesterol levels and protects from atherosclerosis.
Byun S; Jung H; Chen J; Kim YC; Kim DH; Kong B; Guo G; Kemper B; Kemper JK
J Biol Chem; 2019 May; 294(22):8732-8744. PubMed ID: 30996006
[TBL] [Abstract][Full Text] [Related]
44. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.
Yao J; Zhou CS; Ma X; Fu BQ; Tao LS; Chen M; Xu YP
World J Gastroenterol; 2014 Oct; 20(39):14430-41. PubMed ID: 25339829
[TBL] [Abstract][Full Text] [Related]
45. Farnesoid X receptor (FXR) activation induces the antioxidant protein metallothionein 1 expression in mouse liver.
Wang B; Zhang H; Luan Z; Xu H; Wei Y; Zhao X; Xing M; Huo X; Zhang J; Su W; Guan Y; Zhang X
Exp Cell Res; 2020 May; 390(1):111949. PubMed ID: 32145254
[TBL] [Abstract][Full Text] [Related]
46. FXR activation alleviates tacrolimus-induced post-transplant diabetes mellitus by regulating renal gluconeogenesis and glucose uptake.
Li L; Zhao H; Chen B; Fan Z; Li N; Yue J; Ye Q
J Transl Med; 2019 Dec; 17(1):418. PubMed ID: 31836014
[TBL] [Abstract][Full Text] [Related]
47. Pregnane X receptor is a target of farnesoid X receptor.
Jung D; Mangelsdorf DJ; Meyer UA
J Biol Chem; 2006 Jul; 281(28):19081-91. PubMed ID: 16682417
[TBL] [Abstract][Full Text] [Related]
48. Ciliogenesis is reciprocally regulated by PPARA and NR1H4/FXR through controlling autophagy in vitro and in vivo.
Liu ZQ; Lee JN; Son M; Lim JY; Dutta RK; Maharjan Y; Kwak S; Oh GT; Byun K; Choe SK; Park R
Autophagy; 2018; 14(6):1011-1027. PubMed ID: 29771182
[TBL] [Abstract][Full Text] [Related]
49. The nuclear bile acid receptor FXR controls the liver derived tumor suppressor histidine-rich glycoprotein.
Deuschle U; Birkel M; Hambruch E; Hornberger M; Kinzel O; Perović-Ottstadt S; Schulz A; Hahn U; Burnet M; Kremoser C
Int J Cancer; 2015 Jun; 136(11):2693-704. PubMed ID: 25363753
[TBL] [Abstract][Full Text] [Related]
50. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
51. Bile salt excretory pump: biology and pathobiology.
Suchy FJ; Ananthanarayanan M
J Pediatr Gastroenterol Nutr; 2006 Jul; 43 Suppl 1():S10-6. PubMed ID: 16819395
[TBL] [Abstract][Full Text] [Related]
52. Nutrient-sensing nuclear receptors PPARα and FXR control liver energy balance.
Preidis GA; Kim KH; Moore DD
J Clin Invest; 2017 Apr; 127(4):1193-1201. PubMed ID: 28287408
[TBL] [Abstract][Full Text] [Related]
53. Farnesoid X receptor induces cell death and sensitizes to TRAIL-induced inhibition of growth in colorectal cancer cells through the up-regulation of death receptor 5.
Hotta M; Sakatani T; Ishino K; Wada R; Kudo M; Yokoyama Y; Yamada T; Yoshida H; Naito Z
Biochem Biophys Res Commun; 2019 Nov; 519(4):824-831. PubMed ID: 31561852
[TBL] [Abstract][Full Text] [Related]
54. Bile acid treatment and FXR agonism lower postprandial lipemia in mice.
Farr S; Stankovic B; Hoffman S; Masoudpoor H; Baker C; Taher J; Dean AE; Anakk S; Adeli K
Am J Physiol Gastrointest Liver Physiol; 2020 Apr; 318(4):G682-G693. PubMed ID: 32003602
[TBL] [Abstract][Full Text] [Related]
55. Consumption of soy protein isolate reduces hepatic SREBP-1c and lipogenic gene expression in wild-type mice, but not in FXR-deficient mice.
Hashidume T; Sasaki T; Inoue J; Sato R
Biosci Biotechnol Biochem; 2011; 75(9):1702-7. PubMed ID: 21897047
[TBL] [Abstract][Full Text] [Related]
56. CREB-upregulated lncRNA MEG3 promotes hepatic gluconeogenesis by regulating miR-302a-3p-CRTC2 axis.
Zhu X; Li H; Wu Y; Zhou J; Yang G; Wang W; Kang D; Ye S
J Cell Biochem; 2019 Mar; 120(3):4192-4202. PubMed ID: 30260029
[TBL] [Abstract][Full Text] [Related]
57. Studies in mice, hamsters, and rats demonstrate that repression of hepatic apoA-I expression by taurocholic acid in mice is not mediated by the farnesoid-X-receptor.
Gardès C; Blum D; Bleicher K; Chaput E; Ebeling M; Hartman P; Handschin C; Richter H; Benson GM
J Lipid Res; 2011 Jun; 52(6):1188-1199. PubMed ID: 21464203
[TBL] [Abstract][Full Text] [Related]
58. Farnesoid X receptor regulates SULT1E1 expression through inhibition of PGC1α binding to HNF4α.
Wang S; Yuan X; Lu D; Guo L; Wu B
Biochem Pharmacol; 2017 Dec; 145():202-209. PubMed ID: 28912067
[TBL] [Abstract][Full Text] [Related]
59. Probucol ameliorates hepatic stellate cell activation and autophagy is associated with farnesoid X receptor.
Yang R; Hu Z; Zhang P; Wu S; Song Z; Shen X; Wei Z
J Pharmacol Sci; 2019 Feb; 139(2):120-128. PubMed ID: 30638990
[TBL] [Abstract][Full Text] [Related]
60. A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity.
Kim DH; Xiao Z; Kwon S; Sun X; Ryerson D; Tkac D; Ma P; Wu SY; Chiang CM; Zhou E; Xu HE; Palvimo JJ; Chen LF; Kemper B; Kemper JK
EMBO J; 2015 Jan; 34(2):184-99. PubMed ID: 25425577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
